Case Report: Tocilizumab Treatment for VEXAS Syndrome With Relapsing Polychondritis: A Single-Center, 1-Year Longitudinal Observational Study In Japan
Front Immunol. 2022 Jun 13;13:901063. doi: 10.3389/fimmu.2022.901063. eCollection 2022.ABSTRACTVacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome is an autoinflammatory disease caused by somatic variants in the UBA1 gene that lead to severe systemic inflammation and myelodysplastic syndrome. Although no standard therapy has been established yet, azacitidine and bone marrow transplantation have been reported to be promising possibilities; however, the indications for these treatments are problematic and not necessarily applicable to all patients. We previously reported the results of short-term treatm...
Source: Herpes - June 30, 2022 Category: Infectious Diseases Authors: Yosuke Kunishita Yohei Kirino Naomi Tsuchida Ayaka Maeda Yuichiro Sato Kaoru Takase-Minegishi Ryusuke Yoshimi Hideaki Nakajima Source Type: research
Tocilizumab in Recalcitrant Bilateral Scleritis in a Case of Relapsing Polychondritis: A 17-year Follow Up
CONCLUSION: Relapsing polychondritis has a well-known association with scleritis. The ocular disease may precede systemic symptoms in some cases. Newer agent such as tocilizumab appears to be effective in controlling this relentless and recurrent disease.PMID:35695904 | DOI:10.1080/09273948.2022.2058555 (Source: Ocular Immunology and Inflammation)
Source: Ocular Immunology and Inflammation - June 13, 2022 Category: Allergy & Immunology Authors: Mariya Doctor Somasheila I Murthy Liza Rajasekhar Source Type: research
Comparison of relapsing polychondritis patients with and without respiratory involvement based on chest computed tomography: a retrospective cohort study
The objective of this study was to compare the clinical features and disease patterns between a res... (Source: BMC Pulmonary Medicine)
Source: BMC Pulmonary Medicine - June 8, 2022 Category: Respiratory Medicine Authors: Dong Wang, Lujia Guan, Xin Dong, Xiaofan Zhu and Zhaohui Tong Tags: Research Source Type: research
Risk factors for the recurrence of relapsing polychondritis
Although the survival rates of patients with relapsing polychondritis (RP) have increased remarkably, the high recurrence rate remains a significant concern for physicians and patients. This retrospective stud... (Source: Arthritis Research and Therapy)
Source: Arthritis Research and Therapy - May 30, 2022 Category: Rheumatology Authors: Tsuneyasu Yoshida, Hajime Yoshifuji, Mirei Shirakashi, Akiyoshi Nakakura, Kosaku Murakami, Koji Kitagori, Shuji Akizuki, Ran Nakashima, Koichiro Ohmura and Akio Morinobu Tags: Research article Source Type: research
Sequential Involvement of Oculomotor Nerve and Optic Nerve Sheath in Relapsing Polychondritis
No abstract available (Source: Journal of Neuro-Ophthalmology)
Source: Journal of Neuro-Ophthalmology - May 27, 2022 Category: Opthalmology Tags: Clinical Correspondence Source Type: research
Reply Letter - Methylprednisolone pulse therapy for relapsing polychondritis (RP) combined with heart block: myth or reality?
Eur Rev Med Pharmacol Sci. 2022 May;26(9):3061. doi: 10.26355/eurrev_202205_28722.NO ABSTRACTPMID:35587055 | DOI:10.26355/eurrev_202205_28722 (Source: European Review for Medical and Pharmacological Sciences)
Source: European Review for Medical and Pharmacological Sciences - May 19, 2022 Category: Drugs & Pharmacology Authors: J F de Carvalho L C Behrmann Martins A F Cardoso Y Shoenfeld Source Type: research
Reply Letter - Methylprednisolone pulse therapy for relapsing polychondritis (RP) combined with heart block: myth or reality?
Eur Rev Med Pharmacol Sci. 2022 May;26(9):3061. doi: 10.26355/eurrev_202205_28722.NO ABSTRACTPMID:35587055 | DOI:10.26355/eurrev_202205_28722 (Source: Pharmacological Reviews)
Source: Pharmacological Reviews - May 19, 2022 Category: Drugs & Pharmacology Authors: J F de Carvalho L C Behrmann Martins A F Cardoso Y Shoenfeld Source Type: research
Reply Letter - Methylprednisolone pulse therapy for relapsing polychondritis (RP) combined with heart block: myth or reality?
Eur Rev Med Pharmacol Sci. 2022 May;26(9):3061. doi: 10.26355/eurrev_202205_28722.NO ABSTRACTPMID:35587055 | DOI:10.26355/eurrev_202205_28722 (Source: European Review for Medical and Pharmacological Sciences)
Source: European Review for Medical and Pharmacological Sciences - May 19, 2022 Category: Drugs & Pharmacology Authors: J F de Carvalho L C Behrmann Martins A F Cardoso Y Shoenfeld Source Type: research
